OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
69 hedge funds and large institutions have $83.9M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
19% more funds holding
Funds holding: 58 → 69 (+11)
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $88.1M → $83.9M (-$4.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.89M |
| 3 |
Millennium Management
New York
|
+$1.41M |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
+$799K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$605K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$4.27M |
| 2 |
BlackRock
New York
|
-$2.47M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$870K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$218K |
| 5 |
PP
PDT Partners
New York
|
-$147K |
OMED Hedge Fund Activity: Q4 2017 in Review
69 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2017, worth a combined $83.9M — down 4.7% from $88.1M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new OMED positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $18.6M. The largest seller was Adams Street Partners, cutting an estimated $4.27M.
- 69 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2017, up from 58 in Q3 2017.
- Funds reported $83.9M of OncoMed Pharmaceuticals, Inc. stock for Q4 2017, down 4.7% quarter-over-quarter.
- 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2017 was BVF Inc, an estimated $18.6M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2017 was Adams Street Partners, an estimated $4.27M sold.
Based on aggregated 13F filings for Q4 2017.